InauguralInvitation Only
CLL
USFocus Meeting 2027
Two days, 38 people, one room.
May 7 to 8, 2027
San Diego, CA
Dates
May 7-8, 2027
Two-day program
Venue
Hotel TBC
San Diego, CA
Audience
38 by invitation
19 KOLs & 19 fellows
Format
8 sessions · 23 talks
Expert talks, panels + case sessions
A Curated Room: The People Shaping Practice
This inaugural, invitation-only meeting convenes a deliberately small faculty: 19 leading CLL KOLs alongside 19 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The science tracks where treatment is moving: fixed-duration doublets versus triplets, MRD- and ctDNA-guided decisions, BTK degraders and resistance, bispecifics and CAR T in relapsed disease, and Richter transformation. Sessions pair expert talks with a moderated panel, with fellow case presentations woven throughout, sustained, close-quarters engagement rather than a lecture hall.
BTK DegradersMRD & ctDNATP53-Aberrant CLLBispecifics & CAR TRichter TransformationGenomics of CLL
Meeting Co-Chairs
Listed alphabetically by surname
Nitin Jain
MD Anderson Cancer Center, Houston, TX
Susan O'Brien
UCI Health, Orange, CA
Faculty drawn from
MD Anderson · Dana-Farber · Memorial Sloan Kettering · Stanford · Fred Hutch and other leading US cancer centers
38
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
CLL US Focus Meeting 2027
Proposed Faculty
Listed alphabetically by surname
Omar Abdel-Wahab
Memorial Sloan Kettering Cancer Center, New York, NY
Ash Alizadeh
Stanford Medicine, Stanford, CA
Jennifer Brown
Dana-Farber Cancer Institute, Boston, MA
Callie Coombs
UCI Health, Orange, CA
Alexey Danilov
City of Hope, Duarte, CA
Matthew Davids
Dana-Farber Cancer Institute, Boston, MA
Rosalie Griffin
Mayo Clinic, Rochester, MN
Nitin Jain
MD Anderson Cancer Center, Houston, TX
Nicole Lamanna
Columbia University Irving Medical Center, New York, NY
Susan O'Brien
UCI Health, Orange, CA
Erin Parry
Dana-Farber Cancer Institute, Boston, MA
Javier Pinilla-Ibarz
Moffitt Cancer Center, Tampa, FL
Mazyar Shadman
Fred Hutchinson Cancer Center, Seattle, WA
Deborah Stephens
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Eliza Ten Hacken
Weill Cornell Medicine, New York, NY
Meghan Thompson
Memorial Sloan Kettering Cancer Center, New York, NY
William Wierda
MD Anderson Cancer Center, Houston, TX
Jennifer Woyach
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Catherine Wu
Dana-Farber Cancer Institute, Boston, MA
Two Days, Eight Sessions
Proposed Agenda
Presentations20 min
Fellow's Cases10 min
Panel Discussions20 to 30 min
Coffee Breaks30 min
Lunch60 min
Day One · Friday, May 7, 2027
Welcome & Opening Remarks
Session IGenomics of CLL
Moderator
Topic TBC
Catherine WuDana-Farber Cancer Institute, Boston, MA
Topic TBC
Eliza Ten HackenWeill Cornell Medicine, New York, NY
Topic TBC
Alexey DanilovCity of Hope, Duarte, CA
Panel Discussion
Coffee Break
Session IIFirstline CLL (1)
Moderator
Firstline CLL
Nitin JainMD Anderson Cancer Center, Houston, TX
How I Manage Firstline TP53 Aberrant CLL
Callie CoombsUCI Health, Orange, CA
Fellow's Case #2
MDACC Fellow
Panel Discussion
Lunch Break + Faculty & Fellow Photo
Session IIIFirstline CLL (2)
Moderator
Doublets vs Triplets: Whom and When?
Jennifer BrownDana-Farber Cancer Institute, Boston, MA
What Next in Firstline CLL?
Mazyar ShadmanFred Hutchinson Cancer Center, Seattle, WA
Fellow's Case #3
Panel Discussion
Coffee Break
Session IVMRD in CLL
Moderator
MRD Techniques: Pros and Cons
William WierdaMD Anderson Cancer Center, Houston, TX
ctDNA, cfDNA: Role in CLL
Ash AlizadehStanford Medicine, Stanford, CA
Fellow's Case #4
Panel Discussion
Day Two · Saturday, May 8, 2027
Session VRelapsed CLL: Novel Therapies
Moderator
BTK Degraders in CLL
Matthew DavidsDana-Farber Cancer Institute, Boston, MA
BTK Degrader Resistance
Omar Abdel-WahabMemorial Sloan Kettering Cancer Center, New York, NY
Bispecifics in CLL
Meghan ThompsonMemorial Sloan Kettering Cancer Center, New York, NY
Panel Discussion
Coffee Break
Session VIRelapsed CLL: FDA-Approved Strategies
Moderator
Pirto in Relapsed CLL
Nicole LamannaColumbia University Irving Medical Center, New York, NY
CAR T in Relapsed CLL
Javier Pinilla-IbarzMoffitt Cancer Center, Tampa, FL
Fellow's Case #6
Panel Discussion
Lunch Break + Faculty & Fellow Photo
Session VIIRichter Transformation
Moderator
Genomics of Richter
Erin ParryDana-Farber Cancer Institute, Boston, MA
Treatment of Richter
Deborah StephensUNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC
Fellow's Case #7
Panel Discussion
Coffee Break
Session VIIINext 5 Years in CLL
Moderator
CHIP in CLL
Rosalie GriffinMayo Clinic, Rochester, MN
Next Questions in CLL Treatment
Jennifer WoyachThe Ohio State University Comprehensive Cancer Center, Columbus, OH
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →
Your Point of Contact
Zeynep Aydagül
Account Executive, MD Education
zeynep.aydagul@md-education.com